Cold urticaria in a pediatric cohort: Clinical characteristics, management, and natural history

Pediatr Allergy Immunol. 2022 Mar;33(3):e13751. doi: 10.1111/pai.13751.

Abstract

Background: Cold urticaria (coldU) is associated with substantial morbidity and risk of fatality. Data on coldU in children are sparse. We aimed to evaluate the clinical characteristics, management, risk of associated anaphylaxis, and resolution rate of coldU in a pediatric cohort. Additionally, we sought to compare these metrics to children with chronic spontaneous urticaria (CSU).

Methods: We prospectively enrolled children with coldU from 2013-2021 in a cohort study at the Montreal Children's Hospital and an affiliated allergy clinic. Data for comparison with participants with solely CSU were extracted from a previous study. Data on demographics, comorbidities, severity of presentation, management, and laboratory values were collected at study entry. Patients were contacted yearly to assess for resolution.

Results: Fifty-two children with cold urticaria were recruited, 51.9% were female and the median age of symptom onset was 9.5 years. Most patients were managed with second-generation H1-antihistamines (sgAHs). Well-controlled disease on sgAHs was negatively associated with concomitant CSU (adjusted odds ratio (aOR) = 0.69 [95%CI: 0.53, 0.92]). Elevated eosinophils were associated with cold-induced anaphylaxis (coldA; aOR = 1.38 [95%CI: 1.04, 1.83]), which occurred in 17.3% of patients. The resolution rate of coldU was 4.8 per 100 patient-years, which was lower than that of CSU (adjusted hazard ratio = 0.43 [95%CI: 0.21, 0.89], p < 10-2 ).

Conclusion: Pediatric coldU bears a substantial risk of anaphylaxis and a low-resolution rate. Absolute eosinophil count and co-existing CSU may be useful predictive factors.

Keywords: anaphylaxis; chronic inducible urticaria; chronic urticaria; cold urticaria; cold-induced urticaria; pediatrics.

MeSH terms

  • Child
  • Chronic Disease
  • Chronic Urticaria*
  • Cohort Studies
  • Comorbidity
  • Female
  • Histamine H1 Antagonists, Non-Sedating*
  • Humans
  • Urticaria* / diagnosis
  • Urticaria* / drug therapy
  • Urticaria* / epidemiology

Substances

  • Histamine H1 Antagonists, Non-Sedating